乳腺癌内分泌辅助治疗相关子宫内膜病变管理指南(2021年版)

2021-08-02 中国抗癌协会 中国实用妇科与产科杂志. 2021,37(08)

背景在我国,乳腺癌发病居女性癌症发病第1位,每年乳腺癌新发病例约7.95万。在诊断年龄上,美国乳腺癌患者的中位诊断年龄为64岁,在我国为48岁,早于美国10~15岁,近60%的患者确诊时为绝经前期。乳

中文标题:

乳腺癌内分泌辅助治疗相关子宫内膜病变管理指南(2021年版)

发布机构:

中国抗癌协会

发布日期:

2021-08-02

简要介绍:

背景在我国,乳腺癌发病居女性癌症发病第1位,每年乳腺癌新发病例约7.95万。在诊断年龄上,美国乳腺癌患者的中位诊断年龄为64岁,在我国为48岁,早于美国10~15岁,近60%的患者确诊时为绝经前期。乳腺癌首选手术治疗,术后内分泌治疗为激素受体阳性乳腺癌重要的辅助治疗手段。2019年版我国指南与规范中,乳腺癌术后内分泌治疗指征为雌激素受体(estrogen receptor,ER)和(或)孕激素受体(progesterone receptor,PR)阳性。60%~75%的乳腺癌患者ER/PR呈阳性,这类ER/PR阳性表达的肿瘤, 

相关资料下载:
[AttachmentFileName(sort=1, fileName=乳腺癌内分泌辅助治疗相关子宫内膜病变管理指南_2021年版_周琦.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f75b11c002161827, title=乳腺癌内分泌辅助治疗相关子宫内膜病变管理指南(2021年版), enTitle=, guiderFrom=中国实用妇科与产科杂志. 2021,37(08), authorId=0, author=, summary=背景在我国,乳腺癌发病居女性癌症发病第1位,每年乳腺癌新发病例约7.95万。在诊断年龄上,美国乳腺癌患者的中位诊断年龄为64岁,在我国为48岁,早于美国10~15岁,近60%的患者确诊时为绝经前期。乳, cover=https://img.medsci.cn/2021825/1629820993940_2020535.jpg, journalId=0, articlesId=null, associationId=18, associationName=中国抗癌协会, associationIntro=中国抗癌协会是中国科学技术协会主管、中华人民共和国民政部注册登记、具有独立法人资格的肿瘤学科唯一的国家一级学会。成立以来积极开展肿瘤学科的临床与基础性研究,创建肿瘤专业继续教育基地,创办多种形式的肿瘤学习培训班,积极推广新成果、新技术,举办国内外肿瘤学术会议,为国内外肿瘤研究者提供了广阔的学术交流平台,促进了我国肿瘤防治水平的提高。, copyright=0, guiderPublishedTime=Mon Aug 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>背景在我国,乳腺癌发病居女性癌症发病第1位,每年乳腺癌新发病例约7.95万。在诊断年龄上,美国乳腺癌患者的中位诊断年龄为64岁,在我国为48岁,早于美国10~15岁,近60%的患者确诊时为绝经前期。乳腺癌首选手术治疗,术后内分泌治疗为激素受体阳性乳腺癌重要的辅助治疗手段。2019年版我国指南与规范中,乳腺癌术后内分泌治疗指征为雌激素受体(estrogen receptor,ER)和(或)孕激素受体(progesterone receptor,PR)阳性。60%~75%的乳腺癌患者ER/PR呈阳性,这类ER/PR阳性表达的肿瘤,&nbsp;</p>, tagList=[TagDto(tagId=285, tagName=乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=285, guiderKeyword=乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=15509, appHits=120, showAppHits=0, pcHits=1130, showPcHits=15389, likes=1, shares=16, comments=9, approvalStatus=1, publishedTime=Wed Aug 25 00:30:48 CST 2021, publishedTimeString=2021-08-02, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Wed Aug 25 00:03:21 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 07:14:15 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=乳腺癌内分泌辅助治疗相关子宫内膜病变管理指南_2021年版_周琦.pdf)])
乳腺癌内分泌辅助治疗相关子宫内膜病变管理指南_2021年版_周琦.pdf
下载请点击:
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1199792, encodeId=f94b1199e9292, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:06:36 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199791, encodeId=a8681199e910b, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:05:55 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011653, encodeId=a280101165376, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Thu Aug 26 10:22:15 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011423, encodeId=5c4e101142345, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d005540744, createdName=ms4000000151524829, createdTime=Wed Aug 25 17:25:41 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011225, encodeId=8b441011225e1, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210825/25feeda2e26248f88951810c40bb87af/985cea2ebc7f46b1bde069164ef7e07a.jpg, createdBy=145a5584307, createdName=张华晟, createdTime=Wed Aug 25 08:59:16 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2022-03-06 ms1000000508304648

    实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1199792, encodeId=f94b1199e9292, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:06:36 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199791, encodeId=a8681199e910b, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:05:55 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011653, encodeId=a280101165376, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Thu Aug 26 10:22:15 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011423, encodeId=5c4e101142345, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d005540744, createdName=ms4000000151524829, createdTime=Wed Aug 25 17:25:41 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011225, encodeId=8b441011225e1, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210825/25feeda2e26248f88951810c40bb87af/985cea2ebc7f46b1bde069164ef7e07a.jpg, createdBy=145a5584307, createdName=张华晟, createdTime=Wed Aug 25 08:59:16 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2022-03-06 ms1000000508304648

    实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1199792, encodeId=f94b1199e9292, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:06:36 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199791, encodeId=a8681199e910b, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:05:55 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011653, encodeId=a280101165376, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Thu Aug 26 10:22:15 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011423, encodeId=5c4e101142345, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d005540744, createdName=ms4000000151524829, createdTime=Wed Aug 25 17:25:41 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011225, encodeId=8b441011225e1, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210825/25feeda2e26248f88951810c40bb87af/985cea2ebc7f46b1bde069164ef7e07a.jpg, createdBy=145a5584307, createdName=张华晟, createdTime=Wed Aug 25 08:59:16 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2021-08-26 ms9000001873897494

    非常实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1199792, encodeId=f94b1199e9292, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:06:36 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199791, encodeId=a8681199e910b, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:05:55 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011653, encodeId=a280101165376, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Thu Aug 26 10:22:15 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011423, encodeId=5c4e101142345, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d005540744, createdName=ms4000000151524829, createdTime=Wed Aug 25 17:25:41 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011225, encodeId=8b441011225e1, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210825/25feeda2e26248f88951810c40bb87af/985cea2ebc7f46b1bde069164ef7e07a.jpg, createdBy=145a5584307, createdName=张华晟, createdTime=Wed Aug 25 08:59:16 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2021-08-25 ms4000000151524829

    学习了#学习#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1199792, encodeId=f94b1199e9292, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:06:36 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199791, encodeId=a8681199e910b, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62945465196, createdName=ms1000000508304648, createdTime=Sun Mar 06 01:05:55 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011653, encodeId=a280101165376, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Thu Aug 26 10:22:15 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011423, encodeId=5c4e101142345, content=学习了<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d005540744, createdName=ms4000000151524829, createdTime=Wed Aug 25 17:25:41 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011225, encodeId=8b441011225e1, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210825/25feeda2e26248f88951810c40bb87af/985cea2ebc7f46b1bde069164ef7e07a.jpg, createdBy=145a5584307, createdName=张华晟, createdTime=Wed Aug 25 08:59:16 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2021-08-25 张华晟

    不错

    0

拓展阅读

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组(统称) · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2010版)

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议:乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南:乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南:激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12